India · Delayed Price · Currency is INR Evonile Pharma Statistics
Total Valuation
Evonile Pharma has a market cap or net worth of INR 43.52 billion. The enterprise value is 48.45 billion.
| Market Cap | 43.52B |
| Enterprise Value | 48.45B |
Important Dates
The last earnings date was Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evonile Pharma has 24.69 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 24.69M |
| Shares Outstanding | 24.69M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 0.68% |
| Float | 6.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.08 |
| PB Ratio | 5.64 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 25.16 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.56 |
| EV / EBITDA | 111.92 |
| EV / EBIT | 122.38 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.43, with a Debt / Equity ratio of 1.03.
| Current Ratio | 0.43 |
| Quick Ratio | 0.27 |
| Debt / Equity | 1.03 |
| Debt / EBITDA | 18.39 |
| Debt / FCF | n/a |
| Interest Coverage | 6.66 |
Financial Efficiency
Return on equity (ROE) is -0.52% and return on invested capital (ROIC) is -11.72%.
| Return on Equity (ROE) | -0.52% |
| Return on Assets (ROA) | 1.54% |
| Return on Invested Capital (ROIC) | -11.72% |
| Return on Capital Employed (ROCE) | 3.70% |
| Weighted Average Cost of Capital (WACC) | 5.17% |
| Revenue Per Employee | 58.38M |
| Profits Per Employee | -700,000 |
| Employee Count | 57 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.95 |
Taxes
In the past 12 months, Evonile Pharma has paid 58.90 million in taxes.
| Income Tax | 58.90M |
| Effective Tax Rate | 310.00% |
Stock Price Statistics
The stock price has increased by +105.40% in the last 52 weeks. The beta is 0.39, so Evonile Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +105.40% |
| 50-Day Moving Average | 1,873.25 |
| 200-Day Moving Average | 1,363.78 |
| Relative Strength Index (RSI) | 45.00 |
| Average Volume (20 Days) | 3,067 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Evonile Pharma had revenue of INR 3.33 billion and -39.90 million in losses. Loss per share was -1.62.
| Revenue | 3.33B |
| Gross Profit | 1.29B |
| Operating Income | 395.90M |
| Pretax Income | 19.00M |
| Net Income | -39.90M |
| EBITDA | 432.90M |
| EBIT | 395.90M |
| Loss Per Share | -1.62 |
Balance Sheet
The company has 3.03 billion in cash and 7.96 billion in debt, with a net cash position of -4.93 billion or -199.85 per share.
| Cash & Cash Equivalents | 3.03B |
| Total Debt | 7.96B |
| Net Cash | -4.93B |
| Net Cash Per Share | -199.85 |
| Equity (Book Value) | 7.72B |
| Book Value Per Share | 312.61 |
| Working Capital | -6.83B |
Cash Flow
In the last 12 months, operating cash flow was 1.73 billion and capital expenditures -13.14 billion, giving a free cash flow of -11.41 billion.
| Operating Cash Flow | 1.73B |
| Capital Expenditures | -13.14B |
| Depreciation & Amortization | 37.00M |
| Net Borrowing | 7.97B |
| Free Cash Flow | -11.41B |
| FCF Per Share | -461.97 |
Margins
Gross margin is 38.75%, with operating and profit margins of 11.90% and -1.20%.
| Gross Margin | 38.75% |
| Operating Margin | 11.90% |
| Pretax Margin | 0.57% |
| Profit Margin | -1.20% |
| EBITDA Margin | 13.01% |
| EBIT Margin | 11.90% |
| FCF Margin | n/a |
Dividends & Yields
Evonile Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | -0.02% |
| Earnings Yield | -0.09% |
| FCF Yield | -26.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |